This Company Is Reprogramming Your Cells to Be Young Again

TL;DR

• 1

  Old drunk mice acted young again: New Limit says old mice given an alcohol-heavy liver injury protocol were normally sedated for 8 to 12 hours, but after treatment they behaved like young mice and appeared protected from both hangover-like behavior and liver damage.

• 2

  The company is betting on reprogramming without turning cells into tumors: Jacob Kimmel explains that Yamanaka's four factors can reset age and cell identity together, which is dangerous in the body, so New Limit built AI and wet-lab systems to find new transcription factor combinations that make old liver, T, and endothelial cells young while keeping them the same cell type.

• 3

  Human testing is close: After raising about $175 million previously and another $435 million now from investors including Founders Fund and Thrive Capital, New Limit says it plans to dose its first human patient in 2027 in a liver disease trial likely starting in Australia.

• 4

  The liver was the first big win because delivery already works there: The therapy uses mRNA packed in lipid nanoparticles, a well-established approach for hepatocytes, which let New Limit move quickly from transcription factor ideas to drug-like molecules and test them in mouse models and mice with humanized livers.

• 5

  New Limit thinks AI is giving biotech its 'AlexNet moment': Kimmel compares epigenetic reprogramming today to deep learning around 2012, saying the field is obviously important to insiders and now getting the first mainstream attention, while New Limit's Ambrosia model predicts useful transcription factor sets from text, protein, DNA, and experimental data.

• 6

  Kimmel sees AI-native biotechs, not OpenAI replacing Eli Lilly overnight: He argues the most likely future is new AI-first therapeutics companies partnering with pharma, much like Genentech-era biotech did after recombinant DNA, rather than foundation model labs becoming end-to-end drug giants by themselves.